Does Medicare cover GLP-1 for weight loss? Yes, for some people through the Medicare GLP-1 Bridge. Eligible patients pay $50 for a monthly supply of a listed brand. The program has specific health and drug-plan requirements. Compounded GLP-1 prescriptions are outside it.
GLP-1 medicines act on a hormone signal involved in appetite and blood sugar. As of September 10, 2026, the day this article was written, the Bridge is operating following its July 1 launch. CMS's announcement, dated July 1, 2026, sets the end date at December 31, 2027.
Does Medicare cover GLP-1 for weight loss in 2026?
The new answer is a limited yes. The Bridge is a temporary Medicare program that pays separately from Part D, Medicare's prescription-drug benefit. A patient still needs an eligible Part D plan, such as a standalone drug plan or a Medicare Advantage coordinated care plan with drug coverage. The plan does not have to volunteer for the Bridge. CMS explains the separate payment route.
The current Medicare product list is specific:
| Brand | Form included in the Bridge |
|---|---|
| Zepbound, containing tirzepatide | KwikPen only; single-dose pens and vials are excluded |
| Wegovy, containing semaglutide | Injections and tablets |
| Foundayo, containing orforglipron | Tablets |
Ozempic, Rybelsus and Mounjaro are not on that Bridge list. Sharing an ingredient with a listed brand doesn't make another product eligible.
Promise's tirzepatide and semaglutide are dispensed as compounded medications, meaning a pharmacy prepares them for an individual prescription. Each is different from an FDA-approved product: the formulation offered here is not FDA-approved. FDA explains that distinction. Through Promise, these are separate prescriptions paid out of pocket. Branded products have their own cash-price channel as well; TrumpRx GLP-1 prices lists them.
Who qualifies for the Medicare GLP-1 Bridge?
The health criteria use BMI, a measure of weight relative to height, when GLP-1 treatment begins. Adults must be at least 18 and meet one of these thresholds:
| Starting BMI | Additional condition required |
|---|---|
| 35 or higher | None from the lists below |
| 30 or higher | Heart failure with preserved ejection fraction, meaning the heart pumps but fills poorly; uncontrolled high blood pressure; or chronic kidney disease at stage 3a or higher, meaning at least moderately reduced kidney function |
| 27 or higher | Prediabetes, meaning blood sugar above normal but below the diabetes range; a previous heart attack or stroke; or peripheral artery disease with symptoms, meaning narrowed arteries in the arms or legs |
CMS defines uncontrolled blood pressure here as a top reading above 140 or a bottom reading above 90 despite two blood-pressure medicines. The provider also confirms ongoing structured nutrition and physical activity. These are CMS's clinical criteria, on its provider page last modified August 6, 2026.
Meeting a BMI threshold alone does not settle eligibility. Certain diagnoses and previous Part D coverage send the prescription through a different route, explained below.
What the $50 actually pays for
The copay, the patient's share of the bill, covers one 28- or 30-day drug supply. The Part D deductible does not apply, and the payment does not count toward Part D's annual out-of-pocket limit. Extra Help, Medicare's assistance program for people with limited income, does not lower it. Medicare lists these cost rules.
As of September 10, 2026, the day this article was written, CMS's pharmacy guidance, last modified August 17, 2026, adds a practical detail: KwikPen needles are a separate purchase. They are not covered by the Bridge or Part D. The program also does not reimburse patients directly for purchases made outside its billing process.
The $245 figure in government announcements is the manufacturer's net monthly price to the program, after discounts. It is not the patient's copay. CMS's Part D guidance confirms that figure.
How a Bridge prescription gets approved
A provider sends the branded prescription, such as Wegovy, to the pharmacy. The pharmacy submits a Bridge claim, then requests prior authorization, the review that decides whether coverage criteria are met. The provider supplies the medical information. A Part D denial is not required first. CMS describes that sequence.
A prescription for compounded semaglutide follows its own pharmacy process and remains outside this Medicare program.
When a prescription still goes through Part D
The reason for prescribing matters. CMS excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, meaning repeated airway blockage during sleep, or qualifying MASH, fatty-liver inflammation with moderate-to-advanced scarring but without cirrhosis, its most advanced stage. Those diagnoses belong in the Part D coverage process. A plan denial does not make the person eligible for the Bridge. CMS spells out that restriction.
Heart disease needs a finer distinction. A past heart attack can meet a Bridge criterion, but a prescription intended to reduce serious heart or stroke events belongs with Part D. The provider records the actual treatment purpose.
The studies show why uses differ. In SELECT, a trial of 17,604 adults with existing heart disease and no diabetes, heart attack, stroke or death from heart and blood-vessel causes occurred in about 6 or 7 per 100 people receiving semaglutide versus 8 per 100 receiving placebo, a treatment without the study drug. The exact rates were 6.5% and 8.0% over an average 39.8 months (Lincoff et al., New England Journal of Medicine, 2023).
In the first SURMOUNT-OSA trial, adults with obesity and sleep apnea had 25.3 fewer breathing interruptions per hour after 52 weeks with tirzepatide, versus 5.3 fewer with placebo (Malhotra et al., New England Journal of Medicine, 2024). Neither trial establishes results for Promise's compounded preparations.
For broader plan questions, the tirzepatide insurance guide explains authorization and coverage terminology.
What this does not mean for compounded prescriptions
Compounded GLP-1s made from bulk ingredients are not Medicare-covered drugs. CMS's Part D manual, section 10.4, excludes bulk drug ingredients from Part D coverage. That is different from saying Medicare never pays for any ingredient in any compounded prescription.
For a beneficiary comparing routes, the distinction is concrete. A branded prescription may go through Part D or the Bridge, depending on the diagnosis and eligibility. A compounded prescription is paid out of pocket; its quoted price is a separate expense. A receipt does not turn it into a covered Zepbound or Wegovy claim.
A licensed provider may still prescribe a compounded formulation within applicable rules; that decision is between the patient and the doctor. The compounded tirzepatide guide explains that individual-prescription route.
At Promise, a licensed U.S. provider reviews every request and may prescribe or decline on medical eligibility; not everyone qualifies.
What to watch after the Bridge
The longer-term program is BALANCE, a voluntary model pairing negotiated medicine prices with lifestyle support. CMS's December 23, 2025 announcement connected it to most-favored-nation pricing agreements. The November 6, 2025 agreement announcement describes that goal as bringing U.S. prices closer to lower prices abroad.
As of September 10, 2026, the day this article was written, CMS's BALANCE page, last modified August 14, 2026, says BALANCE will not launch in Medicare in 2027. The Bridge continues through December 31, 2027. A replacement or extension beyond that date still needs an announced decision; the current program does not promise permanent coverage.